Pache de Faria Guimaraes Luciana, Seguro Antonio Carlos, Shimizu Maria Heloisa Mazzola, Lopes Neri Letícia Aparecida, Sumita Nairo Massakasu, de Bragança Ana Carolina, Aparecido Volpini Rildo, Cunha Sanches Talita Rojas, Macaferri da Fonseca Fernanda Andrade, Moreira Filho Carlos Alberto, Vaisbich Maria Helena
Pediatric Nephrology Unit, Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Pediatr Nephrol. 2014 Jun;29(6):1097-102. doi: 10.1007/s00467-013-2705-3. Epub 2013 Dec 11.
Nephropathic cystinosis is an autosomal recessive systemic severe disease characterized by intralysosomal cystine storage. Cysteamine is an essential component of treatment. There is solid evidence that cystine accumulation itself is not responsible for all abnormalities in cystinosis; there is also a deficiency of glutathione in the cytosol. Patients with cystinosis can be more susceptible to oxidative stress.
CASE-DIAGNOSIS/TREATMENT: The patient cohort comprised 23 cystinosis patients (16 males) aged <18 years (mean age 8.0 ± 3.6 years) with chronic kidney disease class I-IV with good adherence to treatment, including cysteamine. Oxidative stress was evaluated based on the levels of serum thiobarbituric acid-reactive substances (TBARS), and renal function was evaluated based on serum creatinine and cystatin C levels and creatinine clearance (Schwartz formula). N-Acetylcysteine (NAC), an antioxidant drug was given to all patients for 3 months (T1) at 25 mg/kg/day divided in three doses per day. The measured values at just before the initiation of NAC treatment (T0) served as the control for each patient.
Median serum TBARS levels at T0 and T1 were 6.92 (range 3.3-29.0) and 1.7 (0.6-7.2) nmol/mL, respectively (p < 0.0001). In terms of renal function at T0 and T1, serum creatinine levels (1.1 ± 0.5 vs. 0.9 ± 0.5 mg/dL, respectively; p < 0.0001), creatinine clearance (69.7 ± 32.2 vs. T1 = 78.5 ± 33.9 mL/min/1.73 m(2), respectively; p = 0.006), and cystatin c level (1.33 ± 0.53 vs. 1.15 ± 0.54 mg/l, respectively; p = 0.0057) were all significantly different at these two time points. Serum creatinine measurements at 6 (T -6) and 3 months (T -3) before NAC initiation and at 3 (T +3) and 6 months (T +6) after NAC had been withdrawn were also evaluated.
During the 3-month period that our 23 cystinosis patients were treated with NAC, oxidative stress was reduced and renal function significantly improved. No side-effects were detected. Larger and controlled studies are needed to confirm these findings.
肾病性胱氨酸病是一种常染色体隐性全身性严重疾病,其特征为溶酶体内胱氨酸蓄积。半胱胺是治疗的重要组成部分。有确凿证据表明,胱氨酸蓄积本身并非导致胱氨酸病所有异常的原因;细胞溶质中还存在谷胱甘肽缺乏的情况。胱氨酸病患者可能更易受到氧化应激的影响。
病例诊断/治疗:该患者队列包括23名年龄小于18岁(平均年龄8.0±3.6岁)的胱氨酸病患者(16名男性),患有I-IV级慢性肾病,对包括半胱胺在内的治疗依从性良好。基于血清硫代巴比妥酸反应性物质(TBARS)水平评估氧化应激,基于血清肌酐、胱抑素C水平及肌酐清除率(施瓦茨公式)评估肾功能。给所有患者服用抗氧化药物N-乙酰半胱氨酸(NAC),剂量为25mg/kg/天,分三次服用,共3个月(T1)。NAC治疗开始前(T0)的测量值作为每位患者的对照。
T0和T1时血清TBARS水平中位数分别为6.92(范围3.3-29.0)和1.7(0.6-7.2)nmol/mL(p<0.0001)。就T0和T1时的肾功能而言,血清肌酐水平(分别为1.1±0.5与0.9±0.5mg/dL;p<0.0001)、肌酐清除率(分别为69.7±32.2与T1=78.5±33.9mL/min/1.73m²;p=0.006)以及胱抑素C水平(分别为1.33±0.53与1.15±0.54mg/L;p=0.0057)在这两个时间点均有显著差异。还评估了NAC开始前6个月(T-6)和3个月(T-3)以及NAC停药后3个月(T+3)和6个月(T+6)时的血清肌酐测量值。
在我们的23名胱氨酸病患者接受NAC治疗的3个月期间,氧化应激减轻,肾功能显著改善。未检测到副作用。需要开展更大规模的对照研究来证实这些发现。